title: Mupirocin and chlorhexidine resistance in Staphylococcus aureus in patients with community-onset skin and soft tissue infections.
abstract: Decolonization measures, including mupirocin and chlorhexidine, are often prescribed to prevent Staphylococcus aureus skin and soft tissue infections (SSTI). The objective of this study was to determine the prevalence of high-level mupirocin and chlorhexidine resistance in S. aureus strains recovered from patients with SSTI before and after mupirocin and chlorhexidine administration and to determine whether carriage of a mupirocin- or chlorhexidine-resistant strain at baseline precluded S. aureus eradication. We recruited 1,089 patients with community-onset SSTI with or without S. aureus colonization. In addition to routine care, 483 patients were enrolled in a decolonization trial: 408 received intranasal mupirocin (with or without antimicrobial baths), and 258 performed chlorhexidine body washes. Patients were followed for up to 12 months with repeat colonization cultures. All S. aureus isolates were tested for high-level mupirocin and chlorhexidine resistance. At baseline, 23/1,089 (2.1%) patients carried a mupirocin-resistant S. aureus strain and 10/1,089 (0.9%) patients carried chlorhexidine-resistant S. aureus. Of 4 patients prescribed mupirocin, who carried a mupirocin-resistant S. aureus strain at baseline, 100% remained colonized at 1 month compared to 44% of the 324 patients without mupirocin resistance at baseline (P = 0.041). Of 2 patients prescribed chlorhexidine, who carried a chlorhexidine-resistant S. aureus strain at baseline, 50% remained colonized at 1 month compared to 48% of the 209 patients without chlorhexidine resistance at baseline (P = 1.0). The overall prevalence of mupirocin and chlorhexidine resistance is low in S. aureus isolates recovered from outpatients, but eradication efforts were less successful in patients carrying a mupirocin-resistant S. aureus strain at baseline.
authors.affiliation: Departments of Pediatrics, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
authors.forename: Stephanie A
authors.initials: SA
authors.lastname: Fritz
authors.forename: Patrick G
authors.initials: PG
authors.lastname: Hogan
authors.forename: Bernard C
authors.initials: BC
authors.lastname: Camins
authors.forename: Ali J
authors.initials: AJ
authors.lastname: Ainsworth
authors.forename: Carol
authors.initials: C
authors.lastname: Patrick
authors.forename: Madeline S
authors.initials: MS
authors.lastname: Martin
authors.forename: Melissa J
authors.initials: MJ
authors.lastname: Krauss
authors.forename: Marcela
authors.initials: M
authors.lastname: Rodriguez
authors.forename: Carey-Ann D
authors.initials: CA
authors.lastname: Burnham
mesh_terms: D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002353:Carrier State; D002648:Child; D002675:Child, Preschool; D002710:Chlorhexidine / Q000494:pharmacology*; D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000382:microbiology; D004202:Disinfectants / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial / Q000187:drug effects*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D016712:Mupirocin / Q000494:pharmacology*; D016133:Polymerase Chain Reaction; D018461:Soft Tissue Infections / Q000188:drug therapy* / Q000382:microbiology; D013207:Staphylococcal Skin Infections / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D004202:Disinfectants; D016712:Mupirocin; D002710:Chlorhexidine